Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Bohui Biotechnology is a high-tech enterprise specializing in the research, development, and commercialization of regenerative medicine and tissue engineering products. The company focuses on utilizing decellularized extracellular matrix (dECM) technology, specifically derived from porcine small intestinal submucosa (SIS), to create biological scaffolds for tissue repair. Their product portfolio includes biological meshes for hernia repair, dural patches, and wound dressings designed to promote natural tissue regeneration and remodeling. Bohui Biotechnology serves the surgical and regenerative medicine markets, providing advanced alternatives to synthetic permanent implants. The company is recognized as a leader in the Chinese market for non-crosslinked biological tissue repair materials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Bohui Biotechnology.